SC
ORIC icon

Stempoint Capital’s Oric Pharmaceuticals ORIC Stock Holding History

Stempoint Capital’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-166,461
Closed -$2M – 104
2025
Q3 		$2M Sell
166,461
-34,324
-17% -$361K 0.4% 50
2025
Q2 		$2.04M Buy
+200,785
New +$1.35M 0.65% 39

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stempoint Capital's ORIC Position: Q4 2025 in Review

Stempoint Capital sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 166,461 shares — an estimated $2M sold.

Stempoint Capital first reported a position in ORIC in Q2 2025 and held it in 2 quarters. The position peaked at $2.04M in Q2 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

  • Stempoint Capital reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Stempoint Capital sold 166,461 Oric Pharmaceuticals shares in Q4 2025, an estimated $2M.
  • Stempoint Capital first reported a position in Oric Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Stempoint Capital's Oric Pharmaceuticals position peaked at $2.04M in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.